Press Releases / Notices

The company’s press releases sometimes carry information on pharmaceutical drugs and products in the pipeline. Under no circumstances is such information provided to promote or advertise these products or offer medical advice.

NEWS 2017

August 04, 2017 Corporate

Nippon Shinyaku Co., Ltd. announces final completion of a manufacturing plant for highly active solid formulations

 Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, Japan; President: Shigenobu Maekawa) today announced the completion of its new manufacturing plant for highly active solid formulations in the Odawara Central Factory area (hereinafter "the Plant"). The operation of the Plant is scheduled to start in January 2018.

 With completion of the Plant, Nippon Shinyaku will be able to produce tablets containing highly potent active pharmaceutical ingredient (HPAPI) such as Uptravi® Tablets (generic name : selexipag, originally discovered and synthesized by Nippon Shinyaku), and also tablets of other HPAPIs to be developed following Uptravi®. Furthermore, we will use the Plant for our consignment manufacturing business and work on cost reduction in addition to stable product supply.

 The Plant is equipped with state-of-the-art facilities including one of Japan's largest fluidized bed granulating dryer as containment facility and high-speed tableting machine featuring automatic washing and dry cycles, thereby ensures high quality of products while enabling low cost manufacturing by taking advantage of scale.

 The Plant is designed not only to meet a number of regulatory requirements for safety ensuring and environment protection as well as the current GMP standards, but also to limit damages caused by disasters such as earthquake, flood and eruption.

 Following the completion of the Plant, we will further strive to ensure stable supply of our high quality products.